Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD

Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD

ObjectiveTo identify reliable immune-inflammation indicators for distinguishing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) from anti–aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorders (NMOSD). To assess these indicators’ predictive s...

Full description

Bibliographic Details
Main Authors:	Lei Wang, Ruihong Xia, Xiangliang Li, Jingli Shan, Shengjun Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Immunology
Subjects:	myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) neuromyelitis optica spectrum disorders (NMOSD) systemic inflammation response index (SIRI) monocyte-to-lymphocyte ratio (MLR) cerebrospinal fluid (CSF)
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1293100/full

Similar Items

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
by: Maria Schroeder-Castagno, et al.
Published: (2022-10-01)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
by: Diego Cardoso Fragoso, et al.
Published: (2023-06-01)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
by: Giulia Fadda, et al.
Published: (2022-11-01)

Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease (MOGAD)
by: Satomi Hiya, et al.
Published: (2023-06-01)

AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
by: Kerri Prain, et al.
Published: (2019-10-01)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
by: Judith Derdelinckx, et al.
Published: (2021-07-01)

Regional spinal cord volumes and pain profiles in AQP4-IgG + NMOSD and MOGAD
by: Susanna Asseyer, et al.
Published: (2024-01-01)

A Rare Case Report: MOGAD with Optic Neuritis- without Spinal İnvolvement
by: Canan Akünal Türel, et al.
Published: (2023-04-01)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
by: Liuyu Lin, et al.
Published: (2022-07-01)

The difference of the retinal structural and microvascular characteristics in patients with MOGAD-ON and AQP4-ON
by: Yajun Yao, et al.
Published: (2022-08-01)

The diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in children
by: Ünsal Yılmaz
Published: (2024-02-01)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
by: Salvatore Ssemmanda, et al.
Published: (2023-09-01)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
by: Chaithra Malli, et al.
Published: (2023-05-01)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management
by: Wojciech Ambrosius, et al.
Published: (2020-12-01)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
by: Susanna Asseyer, et al.
Published: (2020-08-01)

AQP4-MOG Double-Positive Neuromyelitis Optica Spectrum Disorder: Case Report with Central and Peripheral Nervous System Involvement and Review of Literature
by: Antonio Luca Spiezia, et al.
Published: (2022-11-01)

COVID-19 and the risk of CNS demyelinating diseases: A systematic review
by: Itay Lotan, et al.
Published: (2022-09-01)

MOGAD Involving Cranial Neuropathies: A Case Report and Review of Literature
by: Yangsa Du, et al.
Published: (2022-11-01)

Anti-myelin Oligodendrocyte Glycoprotein in Aquaporin-4 Negative Neuromyelitis Optica Spectrum Disorder
by: Vahid Shaygannejad, et al.
Published: (2021-01-01)

Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients
by: Jonathan D. Santoro, et al.
Published: (2023-04-01)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
by: Luca Bollo, et al.
Published: (2021-03-01)

Differential diagnosis of demyelinating diseases: what's new?
by: Ana Beatriz Ayroza Galvão Ribeiro Gomes, et al.
Published: (2022-08-01)

Efficacy and safety of rituximab in central nervous system demyelinating disorders
by: Varsha A Patil, et al.
Published: (2021-01-01)

Neuromyelitis Optica Spectrum Disorders (NMOSD); Diagnostic criteria (ORP-56)
by: Maryam Poursadeghfard
Published: (2023-01-01)

Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
by: Joachim Havla, et al.
Published: (2021-05-01)

MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
by: Laura Clarke, et al.
Published: (2021-09-01)

Editorial: Epidemiology, diagnosis, prognosis and treatment of rare immune-mediated diseases of the central nervous system
by: Barbara M. P. Willekens, et al.
Published: (2023-12-01)

Editorial: Real-world study of multiple sclerosis and related diseases in developing countries
by: Jinming Han, et al.
Published: (2023-11-01)

NMOSD—Diagnostic Dilemmas Leading towards Final Diagnosis
by: Anna K. Szewczyk, et al.
Published: (2022-07-01)

Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
by: Georges Saab, et al.
Published: (2022-05-01)

Diagnostic challenge in children with an acquired demyelinating syndrome: an illustrative case report
by: Luciana Midaglia, et al.
Published: (2023-07-01)

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and Human Immunodeficiency virus infection: dilemmas in diagnosis and management: a case series
by: Yohane Gadama, et al.
Published: (2023-10-01)

Anti-myelin oligodendrocyte glycoprotein antibodies in a girl with good recovery after five episodes of prior idiopathic optic neuritis
by: Mathias Falck Schmidt, et al.
Published: (2021-06-01)

A retrospective study of myelin oligodendrocyte glycoprotein antibody-associated disease from a clinical laboratory perspective
by: Yufei Wang, et al.
Published: (2023-09-01)

Comparative Analysis of T-Cell Responses to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein in Inflammatory Demyelinating Central Nervous System Diseases
by: Livia Sophie Hofer, et al.
Published: (2020-06-01)

The MOG antibody associated encephalitis preceded by COVID-19 infection; a case study and systematic review of the literature
by: Michał Borończyk, et al.
Published: (2023-08-01)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management
by: Elia Sechi, et al.
Published: (2022-06-01)

Optomyelitis associated with the presence of antibodies to myelin oligodendrocyte glycoprotein. Case report
by: Anastasiia K. Kalashnikova, et al.
Published: (2022-02-01)

The patient journey with NMOSD: From initial diagnosis to chronic condition
by: Guillermo Delgado-Garcia, et al.
Published: (2022-09-01)

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents
by: Renata Barbosa Paolilo, et al.
Published: (2023-02-01)